The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.

On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China will benefit from the AI revolution, from drug development and diagnostics to hospital management.

wallstreetcnFeb 27 16:39

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 27 09:37

Shanghai Bio-heart Biological Technology Gets China Nod for Catheter System

MT NewswiresFeb 26 19:14

Baxin'an-B (02185.HK): The State Drug Administration has approved the registration of the IBERISRDN system.

On February 26, Glenwood reported that Baixin An-B (02185.HK) announced that its subsidiary Shanghai Antong Medical Technology Co., Ltd. (“Antong”) has developed the Iberis multi-polar renal artery radiofrequency ablation system (including single-use multi-polar renal artery radiofrequency ablation catheters and renal artery radiofrequency ablation devices) (“Iberis RDN system”) which has been approved by China's National Medical Products Administration (“National Medical Products Administration”) for assisting in the treatment of patients with resistant hypertension and drug intolerance.

Gelonghui FinanceFeb 26 17:06

Baixinan - B (02185.HK) multi-polar renal artery radiofrequency ablation system has received registration approval.

Baixin An - B (02185.HK) announced that on February 26, the Iberis multipolar renal artery radiofrequency ablation system (Iberis RDN system) developed by its subsidiary Antong has been approved by the National Medical Products Administration for use in assisting the treatment of resistant hypertension and drug intolerant hypertensive patients.

AASTOCKSFeb 26 17:04

Among 174 pharmaceutical items, selected for national Chinese Patent Medicine collection, the implementation will take place in April.

The National Chinese Patent Medicine Joint Procurement Office has announced the results of the third batch of national Chinese Patent Medicine procurement alliance collective selection, revealing that 174 pharmaceutical products were ultimately selected. The collective procurement under the National Chinese Patent Medicine Alliance involves 20 product groups and 95 products. After the announcement of results, regional alliances will be organized to implement the agreed procurement volume and sign purchase-sale contracts and other related work. The results of the national Chinese Patent Medicine alliance collective procurement are expected to be implemented nationwide in April. Among the top 50 Chinese Patent Medicine products ranked by provincial-level platforms, 34 are exclusive varieties. The large number of exclusive products and high concentration result in weak substitutability of collective procurement products of Chinese Patent Medicine, leading to insufficient price reduction motivation for enterprise

AASTOCKSFeb 12 10:41